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Abstract
Background: Cost-utility analyses are commonly used in economic evaluations of interventions or conditions that
have an impact on health-related quality of life. However, evaluating utilities in children presents several challenges
since young children may not have the cognitive ability to complete measurement tasks and thus utility values
must be estimated by proxy assessors. Another solution is to use utilities derived from an adult population. To
better inform the future conduct of cost-utility analyses in paediatric populations, we reviewed the published
literature reporting utilities among children and adults across selected conditions common to paediatric and adult
populations.
Methods: An electronic search of Ovid MEDLINE, EMBASE, and the Cochrane Library up to November 2008 was
conducted to identify studies presenting utility values derived from the Health Utilities Index (HUI) or EuroQoL-
5Dimensions (EQ-5D) questionnaires or using time trade off (TTO) or standard gamble (SG) techniques in children
and/or adult populations from randomized controlled trials, comparative or non-comparative observational studies,
or cross-sectional studies. The search was targeted to four chronic diseases/conditions common to both children
and adults and known to have a negative impact on health-related quality of life (HRQoL).
Results: After screening 951 citations identified from the literature search, 77 unique studies included in our review
evaluated utilities in patients with asthma (n = 25), cancer (n = 23), diabetes mellitus (n = 11), skin diseases (n =
19) or chronic diseases (n = 2), with some studies evaluating multiple conditions. Utility values were estimated
using HUI (n = 33), EQ-5D (n = 26), TTO (n = 12), and SG (n = 14), with some studies applying more than one
technique to estimate utility values. 21% of studies evaluated utilities in children, of those the majority being in the
area of oncology. No utility values for children were reported in skin diseases. Although few studies provided
comparative information on utility values between children and adults, results seem to indicate that utilities may
be similar in adolescents and young adults with asthma and acne. Differences in results were observed depending
on methods and proxies.
Conclusions: This review highlights the need to conduct future research regarding measurement of utilities in
children.
Background
The rising cost of healthcare has led to an increased use
of economic evaluations to evaluate the costs and conse-
quences of healthcare interventions (e.g. pharmacothera-
pies, medical devices). In addition to demonstrating that
a new product is safe and effective, economic evalua-
tions are now required in many constituencies to obtain
reimbursement. When healthcare interventions have an
impact on patients’ health-related quality of life
(HRQoL), several jurisdictions (e.g. Canada, UK) recom-
mend the use of cost-utility analyses (CUAs) as the
r e f e r e n c ec a s e[ 1 ] .I nC U A s ,t h ec o n s e q u e n c e so ft h e
interventions are valued in terms of quality-adjusted
life-years (QALYs) where QALYs are a composite mea-
sure of outcome where utilities for health states (on 0-1
scale where 0 corresponds to death and 1 to full health)
act as qualitative weights to combine quantity with qual-
ity of life.
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utility or health preference associated with particular
health states (e.g., sick). Utilities can be taken from the
literature but values from the literature, if available, may
not always be relevant to the health states and popula-
tion of interest. Utilities can also be derived from expert
opinion when physicians, nurses or other experts are
asked to provide a judgment regarding the utility value
for a disease or a range of health states (e.g. well, sick
and dead). However, because this method has several
limitations (e.g. who’s judgment, how obtained, how
much experience, how consensus is reached), it is
recommended to measure utilities through formal direct
or indirect measurements. Direct measurements involve
the use of standard gamble (SG) or time trade-off
(TTO) techniques to elicit preferences for particular
health states. In both cases, scenarios specific to the
study are developed and face to face interviews are con-
ducted to observe when the individual is indifferent
between a gamble (e.g. live with disease A until death or
receive an intervention which can cure or kill you
immediately with probability p) or a TTO (live with dis-
ease A until death or live a few years less but in a better
health state). Indirect measurements of utility refer to
the use of pre-developed preferences questionnaires
such as the European EuroQoL-5 Dimensions (EQ-5D)
or the Canadian Health Utility Index (HUI) self-admi-
nistered questionnaires. Here, patients (children or
adults) or proxies rate their health-related quality of life
according to the dimensions included in the instrument
(e.g. for example, mobility, self-care, usual activities,
pain/discomfort and anxiety/depression for the EQ-5D).
Patients’ (proxies’) ratings are then converted to a health
utility score using a scoring algorithm based on the pre-
ferences of the general adult public.
Although both direct (i.e. using TTO or SG techni-
ques) and indirect (i.e. using pre-existing questionnaires)
measurements are commonly used when performing
CUAs in adult populations, collecting utilities in chil-
dren and adolescents presents several challenges. Young
children may not have the cognitive ability to complete
measurement tasks and thus proxies (e.g. parents, clini-
cians) are used to estimate HRQoL or utility values [2].
It may also be difficult in some cases to separate the
true effect of a healthcare intervention from the normal
development of the children (e.g. autonomy). Prefer-
ence-based instruments such as the EQ-5D were devel-
oped for adult populations and may not include other
dimensions relevant to children and adolescents (e.g.
body image) [2]. One preference-based instrument
which was specifically developed for use in children
with cancer is the Health Utilities Index Mark (HUI)-2.
Although the Child Health Utility 9D (CHU 9D) instru-
ment was recently developed for use in paediatric
economic evaluations [3], studies using this instrument
to estimate utility values in children have yet to be pub-
lished. It should also be noted that even if the HUI-2 or
t h eC H U 9 Da r ea d m i n i s t e r e d to children, the prefer-
ences used to valuate the children’ ratings into a utility
v i aas c o r i n ga l g o r i t h ma r ed e r i v e df r o mt h ea d u l tg e n -
eral public.
Another alternative to derive utilities for a paediatric
population is to elicit preferences from the general pub-
lic through direct measurements techniques. In this
situation, adults are asked to imagine that they are chil-
dren with a certain disease before being invited to
express their preferences for particular health states
using SG or TTO techniques. However, this task is both
resource intensive (e.g., need to develop health states
scenarios) and time intensive (e.g., 20-30 minutes for
each individual face-to-face interview) compared to pre-
existing questionnaire (3-7 minutes for the EQ-5D or
HUI questionnaires). In addition, these measurements
may be subject to interpretation (e.g. asking an adult to
imagine that he/she is a child with a given disease).
It is therefore not surprising that a review by Griebsch
et al. of 53 cost-utility studies in paediatrics (i.e. patients
were 16 years of age or younger) published before April
2004 reported that authors’ or clinicians’ judgment was
used in 35% of the studies (n = 23) [4]. A smaller pro-
portion (17%) of studies administered the HUI (n = 12)
and the EQ-5D (n = 5) questionnaires while TTO and
SG techniques were the method of choice in 11 studies.
The remaining studies used other methods (n = 7) or
did not state the methods (17% or n = 11). In terms of
the source of the preferences, author/clinician and the
general public represented 40% and 37% respectively of
the sources used to calculate utilities in children under
the age of 16 years [4]. In comparison, 10% of the stu-
dies used preferences from adult patients, 5% used par-
ents as proxies and only 2% of the studies used children
as the source of the preferences. These results should,
however, be interpreted with caution as half of these 53
cost-utility analyses evaluated healthcare interventions
for newborns (e.g. vaccination programs). Another
recent review of HRQoL measurements (including gen-
eric and disease-specific instruments) in children and
adolescents by Solans et al. confirmed that few studies
measured utilities in paediatric populations [5]. Out of
the 94 HRQoL instruments for children and adolescents
reviewed in this publication, the HUI was cited once
and no study used the EQ-5D questionnaire or the
TTO or the SG method.
When performing a cost-utility analysis in a paediatric
population, and in the absence of primary utility data (e.
g. derived from a trial), the analyst is faced with a diffi-
cult question regarding the determination of the utilities.
Although expert opinion has been commonly used in
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ment values have several limitations. On the other hand,
direct measurements are time and resource intensive
while most self-administered questionnaires are not
applicable to a non-adult population. Furthermore, for
young children who may not have the cognitive ability
to answer questionnaires or participate in an interview,
proxies need to be used. Another approach that has
been used is to estimate utilities from adult patients. To
gain a better understanding of the use of these methods
in paediatric populations and to inform future cost-uti-
lity analyses in these populations, we systematically
reviewed the published literature reporting utilities
derived from direct (i.e. TTO and SG) and indirect (i.e.
EQ-5D and HUI) measurements across conditions com-
mon in paediatric and adult populations.
Methods
Studies presenting utility values derived from HUI or
EQ-5D or using TTO or SG techniques in children and/
or adult populations from randomized controlled trials
(RCTs), comparative or non-comparative observational
studies, or cross-sectional studies were included in the
review. Although utilities can be derived from other
questionnaires such as the SF-12 [6], the SF-6D [7] or
the newly developed Assessment of Quality of Life
(AQoL) [8], our search focussed on the HUI and EQ-5D
and these two instruments are the most commonly used
utility instruments for economic evaluations [4,9]. The
search was limited to selected chronic diseases/condi-
tions common to both children and adults [10,11], and
known to have a decremental impact on health-related
quality of life. These included skin diseases and asthma,
two highly prevalent conditions in children and adults,
as well as cancer and diabetes. Although less prevalent
than asthma or skin diseases, cancer and diabetes ser-
iously impact HRQoL and were included as well. Studies
evaluating patients with chronic diseases were also
included if the study population had patients with one
of the above mentioned diseases. While the literature
search strategy identified studies related to diabetes mel-
litus and all types of cancer, studies were excluded if
they assessed only patients with type 2 diabetes or if the
type of cancer affects only adults (e.g. colorectal, breast)
since no comparison can be made with a paediatric
population. Studies using the EQ-5D visual analogue
s c a l e( V A S )a l o n ew e r ee x c l u d e da st h ev a l u ed e r i v e d
from a VAS cannot directly be used as a utility without
a transformation.
An electronic search of Ovid MEDLINE (1950-pre-
sent), EMBASE (1980-present), and the Cochrane
Library (via Wiley) was conducted to identify relevant
citations published up to November 2008. A search
strategy was developed for each electronic database
using specific subject headings in addition to relevant
text keywords. The detailed search strategies are shown
in Additional file 1, Table S1: Electronic Database
Search Strategies. No language restrictions were placed
on the database searches. Study citations were down-
loaded into a Reference Manager 11® database and all
duplicate citations were identified and removed. One
reviewer screened titles, abstracts and full-text versions
of identified studies to determine study eligibility. A
QUORUM diagram was used to summarize the study
selection process. Data abstraction was completed by
one reviewer and all data collected was verified by a sec-
ond reviewer.
Included studies were classified based on the disease/
condition, the population (children, adults, both), the
type of utility measurement (EQ-5D, HUI, TTO, SG)
and the level of evidence (RCT, observational, longitudi-
nal, cross-sectional). The difference in utility gains/losses
over time was captured for all prospective studies (e.g.
utility at study end versus utility as study start). Where
the change in utilities over time was not available (e.g.
cross sectional studies), the mean utility values were
recorded. Comparisons between children/adolescents
and adults were assessed for studies evaluating both
populations. Given the heterogeneity of included studies
in terms of disease, population, and study design, the
results of the literature review were summarized using a
narrative approach. Similarly, the quality of individual
studies was not assessed due to the heterogeneity of
study designs, as there is no single tool available to eval-
uate the methodological quality of RCTs, non-rando-
mized trials, cross-sectional studies and population
health surveys. For the purposes of this study, subjects
aged 18 years or less were defined as children/
adolescents.
Results
The literature search identified 951 citations of which
808 were excluded based on title and abstract screening.
Out of the 143 studies which underwent full text review,
66 were excluded resulting in 77 studies included in our
review. A flow diagram presenting information about
the number of studies identified, included and excluded,
and reasons for exclusion is shown in Figure 1. Table 1
presents an overview of studies included in our review
in terms of medical condition, population, utility mea-
sure and study design.
Overall, 21% of the studies evaluated both adults and
children (n = 16), 23% evaluated children (n = 18) and
56% of the included studies evaluated an adult popula-
tion only (n = 43). Direct measurements (i.e., SG, TTO)
were used 31% of the time, while utilities were estimated
using indirect methods (i.e., EQ-5D, HUI) 69% of the
time (Figure 2). Although there were a higher
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pared to the EQ-5D instrument, the HUI instrument
was primarily used in the evaluation of cancer patients.
The results of selected studies are discussed by condi-
tion in the following sections. Each section begins by an
overall overview of the identified studies, followed by a
brief description of the studies starting with studies
using indirect measurements (e.g. using the EQ-5D or
the HUI) and then studies using direct measurements
methods (e.g. TTO or SG). Further details of all
included studies are shown in Additional files 2, 3, 4, 5,
6 (Tables S2-S6).
Asthma
Of the 25 studies that reported utility values in patients
with asthma, 5 included children and adults [10,12-15],
one study evaluated children alone [16], and the remain-
ing 19 studies evaluated adults only [17-35] (Additional
file 2, Table S2-Utilities derived for asthma).
One study conducted in the Netherlands by Willems
et al. [15], administered the EQ-5D instrument to chil-
dren and adults enrolled into a RCT examining the
effect of nurse-led telemonitoring versus usual outpati-
ent care over 12 months. Results indicated that children
and adults in the control groups had a similar improve-
ment in EQ-5D utility of 0.01 points during the 12-
month follow-up (from 0.78 (SD 0.17) to 0.79 (SD 0.21)
for adults and from 0.96 (SD 0.07) to 0.97 (SD 0.05) for
children). Although a change of 0.01 points is not con-
sidered a clinically important difference [36], this study
suggests a similar gain in utilities between children and
adults in an asthmatic population treated with usual
care. The same study also showed that the gain in utility
observed in the intervention group was higher in the
paediatric population than in the adult population.
However, it is unknown if these results reflect the fact
that this nurse-led telemonitoring program was not
effective in adults or if adults coped better with the dis-
ease than children.
The other four studies reporting utility data in chil-
dren and adults with asthma had a cross-sectional
study design and were undertaken in the US or
Canada [10,12-14]. In the 1999 study by Mittmann et
al., results indicated that HUI utility scores in asth-
matic patients 12-19 years of age (mean: 0.90; SD 0.12)
were similar to that of patients 20 to 29 years old
(mean: 0.91; SD 0.11). Utility values associated with
asthma decreased with the age of patients (e.g. 0.84 for
40-49 years of age and 0.76 for 60-69 years of age).
Two other studies conducted in Canada reported utili-
ties of 0.87 to 0.96 for asthmatic patients aged 12 years
and over, using the HUI instrument. While the data
was also collected through a national health survey, no
breakdown by age or disease severity was provided. In
the study by Chiou et al. [12], results were reported
Potentially relevant citations identified from the 
electronic databases (n= 951)
Full-text articles reviewed
(n= 143)
Citations excluded based on title and abstract (n= 808)
Other disease (349)
Adult cancer (253)
No EQ-5D, HUI, TTO or SG (116)
Modeling study (18)
Other (72)
Citations included in review
(n= 77)
Citations excluded after full-text review (n= 66)
No QoLfor disease state (12)
Validity and reliability study (9)
Type 2 diabetes (8)
Other disease (8)
Other (29)
Figure 1 Flow diagram for review of utilities derived using EQ-5D, HUI, TTO and SG.
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years and a mean age of 38 years using the SG techni-
que. SG utilities for a health state with moderate
symptoms were higher for the adult cohort compared
with children (0.96 versus 0.79), suggesting a greater
impact of the disease on children.
Juniper et al. [16] evaluated utilities in a younger
population (mean age: 12 years) that were recruited
from a paediatric asthma clinic in Canada using the
HUI instrument and SG technique. Results indicated
differences between methods as the mean utility values
were 0.89 (SD 0.09) using the HUI instrument and 0.82
(SD 0.15) using the SG technique. However, the mean
values were close to the mean HUI and SG utility values
of 0.90 and 0.79 reported by children and adolescents in
the studies by Mittman et al. [10] and Chiou et al. [12],
respectively.
Of the 19 studies reporting utility values associated
with asthma in adults, 14 studies used an existing pre-
ference-based instrument (e.g. EQ-5D and/or HUI)
[17,19,20,23-25,27-29,31-35] and utilities ranged from
0.33 to 0.92 reflecting different populations, disease
severity or study settings. In general, studies found that
adult patients with poor control of their disease had a
lower quality of life [26,28,29,35].
Cancer
Twenty-three studies estimated utility values associated
with cancer using the HUI2 or HUI3 instrument (Addi-
tional file 3, Table S3-Utilities derived for cancer)
[14,37-58]. Eleven studies evaluated children and adults
using a cross-sectional study design. With the exception
of one study which captured cancer utility data from a
national health survey, the other 10 studies determined
the utilities in survivors of childhood cancer at different
survival time periods (e.g. 1 year, 10 years). Of the 12
studies which included children, 4 evaluated patients
enrolled in non-randomized trials who were undergoing
treatment for cancer [38,42,48,58], while 8 studies used
a cross-sectional study design to evaluate children with
cancer or children who had survived cancer
[39,40,46,47,50,54,56,57].
Table 1 Summary of Included Studies (n = 77)
Condition Population No. of studies* Utility Measure Study Design (No. of studies*)
Asthma Adults & children/adolescents 5 EQ-5D RCT (1)
HUI cross-sectional (3)
SG cross-sectional (1)
Children/adolescents 1 HUI non-randomized cohort (1)
SG non-randomized cohort (1)
Adults 19 EQ-5D non-randomized cohort (2); cross-sectional (9)
HUI cross-sectional (4)
SG cohort (2); cross-sectional (3)
TTO cross-sectional (4)
Cancer Adults & children/adolescents 11 HUI cross-sectional (11)
Children/adolescents 12 HUI non-randomized cohort (4); cross-sectional (8)
SG cross-sectional (1)
TTO cross-sectional (1)
Chronic disease Children/adolescents 2 HUI cross-sectional (2)
TTO cross-sectional (1)
Diabetes Children/adolescents 1 EQ-5D non-randomized cohort (1)
Adults 10 EQ-5D non-randomized cohort (1); cross-sectional (5)
HUI cross-sectional (1)
SG cross-sectional (1)
TTO cross-sectional (3)
Skin diseases Adults & children/adolescents 2 EQ-5D cross-sectional (1)
HUI cross-sectional (1)
Children/adolescents 2 SG cross-sectional (1)
TTO cross-sectional (1)
Adult 15 EQ-5D RCT (4); non-randomized (1); cross-sectional (2)
SG cross-sectional (2); cohort (1); test-retest cohort (1)
TTO cross-sectional (5); cohort (1); pre-post (1)
EQ-5D-EuroQol-5Dimension; HUI-Health Utilities Index; SG-standard gamble; TTO-time trade off; RCT-randomized controlled trial. *Total number of studies is
greater than 77, as some studies evaluated multiple conditions and/or used multiple methods of utility measurement.
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straightforward given the vast differences in patient
characteristics, evaluation periods, cancer types and
treatment patterns. Despite differences in the type of
cancer and the follow-up period, the majority of studies
reported mean utility values greater than 0.8 for survi-
vors of childhood cancer. Survivors of childhood acute
lymphoblastic leukemia or Hodgkin’s disease showed
utility values ranging from 0.72 to 0.91 and from 0.75 to
0.88, respectively, whereas lower utility values were
reported for survivors of germ cell tumours (mean: 0.49)
and retinoblastomas (mean: 0.51-0.78). Five studies eval-
uating utilities using different proxies such as parents,
physicians or nurses [38,43,45,46,52] showed marked
differences in results obtained from different assessors.
Chronic disease
Two studies were identified that determined utility
values of children and adolescents with chronic condi-
tions [59,60]. The aim of these two studies was to exam-
ine the difference in utility estimates dependent on
whether the children themselves or their parents/paedia-
tricians were the assessors. A comparison of the HUI2,
HUI3, and TTO scores by Sung et al. [60] indicated that
for both parents and children, the utilities were higher
with the HUI2 (which was specifically developed for use
in children) while the utilities derived from the HUI3 or
TTO experiments were similar. In addition, this study
showed that utilities derived from children were higher
than those derived from their parents. In another study
[59], utilities derived from paediatricians (mean: 0.93)
were higher than those derived from parents (mean:
0.80). In both studies, utilities derived from parents
were similar in magnitude. Details are presented in
Additional file 4, Table S4-Utilities derived for chronic
disease.
Type 1 diabetes mellitus
Although eleven studies reported utility data associated
with type 1 diabetes mellitus [61-71], only one study
included children (Additional file 5, Table S5-Utilities
derived for diabetes) [70]. In a postal survey of children
enrolled in a prospective cohort study, Nordfeldt et al.
[70] demonstrated that patients with severe hypoglyce-
mia had a median utility of 0.85 and patients without
severe hypoglycemia had a median EQ-5D utility of 1.0,
however, no further details were given in this study
regarding this result (i.e. median utility of 1.0).
Ten studies collected utility data among adults with
type 1 diabetes mellitus. One study employed a cohort
design [66], while the remaining studies had a cross-sec-
tional study design [61-65,67-69,71]. Among all the stu-
dies in adults, the reported utility with preference-based
instruments (i.e. EQ-5D) ranged from 0.52 to 0.90
reflecting difference in study settings and patients’ dis-
ease severity. Four studies [61,62,67,68] using a cross-
sectional study design used either the TTO method or
the SG method in adults with type I diabetes mellitus.
These studies were carried out in the US, UK and
Canada. In the studies by Brown et al. [61], Chancellor
et al. [62], and Landy et al. [68], the results of the TTO
approach were of the same order of magnitude across
studies with a mean utility value of 0.88 (SD 0.117), 0.83
(SD 0.02), and 0.873, respectively.
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Utility data were reported in 19 studies [10,34,72-88]
conducted in the area of skin diseases, of which 15 eval-
uated an adult population (Additional file 6, Table S6-
Utilities derived for skin disease). Two studies evaluated
the utility values for both children/adolescents and
adults with acne [10,76], The EQ-5D was administered
to 54 dermatology clinic patients with severe acne who
were at least 16 years of age (mean age: 22 years) [76].
In this prospective, non-randomized study, patients’
mean utilities increased from a value of 0.84 (standard
deviation (SD) 0.17) at baseline to 0.93 (SD 0.15) after
12 months of acne treatment. However, data was not
presented separately for children and adults. In the 1999
study by Mittmann et al., utility values were presented
for specific conditions (e.g. acne, asthma) using data
from 17,626 Canadians aged 12 to 80+ years who parti-
cipated in the Canadian Community Health Survey
(CCHS) conducted by Statistics Canada [10]. Among
other questions, the CCHS included the HUI instru-
ment. Results indicated that HUI utility scores in acne
patients 12-19 years of age (mean: 0.92; SD 0.90) were
similar to that of patients 20 to 29 years old (mean:
0.92; SD 0.09).
One study determined the utility of children/adoles-
cents with skin disease using the SG technique by deriv-
ing preferences from the general public (mean age: 54
years). In this study, the utility value associated with
children with atopic dermatitis was estimated at 0.84
[85]. In another cross-sectional study of 266 adolescents
with acne conducted at four US high schools, utilities
were estimated to be 0.96 (SD 0.092), based on a TTO
approach [73].
Fifteen studies reported utility data collected in adults.
Of the 7 studies that assessed the quality of life of adults
with skin disease by applying a preference-based instru-
ment [34,72,79,83,84,86,87], all 7 studies used the EQ-
5D questionnaire and 6 of these studies examined
HRQoL of patients with psoriasis. In these 6 studies, the
mean utility ranged from 0.66 to 0.80. Two RCTs that
provided utility data at baseline and after several weeks
of follow-up, during which patients were treated with
either placebo or an active agent, indicated an increase
of 0.2 utility points following 12 weeks of treatment,
which included both responders and non-responders to
treatment [79,84].
Eight studies used direct estimation techniques to
evaluate adult patients’ utilities associated with skin dis-
eases [74,75,77,78,80-82,88], with the majority of these
studies (n = 5) assessing patients with psoriasis. These
studies evaluated adult patients with a mean age
between 28 and 54 years. With the exception of the 3
studies by Littenberg et al. [77], Lundberg et al. [78] and
Schiffner et al. [81], the other 5 studies were cross-
sectional studies. Although not a prospective study, one
study evaluated the utility associated with treatment
response. Based on 58 patients undergoing treatment at
a dermatology outpatient clinic, Schmitt and colleagues
found a difference of 0.43 utility points between patients
in whom psoriasis was controlled by their treatment ver-
s u sn o n - r e s p o n d e r s ,w h i l ead i f f e r e n c eo f0 . 3 1u t i l i t y
points between responders and non-responders was
s h o w ni ne c z e m ap a t i e n t s[ 82]. The impact of disease
severity was assessed in a sample of psoriasis patients
from a tertiary medical centre using both TTO and SG
methods in the study by Zug et al. [88], which demon-
strated a decrease in mean utility values with higher
proportions of body surface area affected by psoriasis.
Discussion
In this review, we identified 77 studies which reported
utility values across conditions that are common in pae-
diatric and adult populations. Although the majority of
these studies evaluated utilities in adult populations,
23% of the studies evaluated utilities in children and a
similar proportion (i.e. 21%) evaluated utilities for both
children/adolescents and adults. When measuring utili-
ties, pre-existing instruments (e.g. HUI, EQ-5D) were
used in two-thirds of the studies. Few studies provided
utilities over time or by response type (e.g. responder to
treatment versus non-responder), which are often
required in economic modelling.
The majority of the studies conducted in children
were among cancer patients and there is a paucity of
utility data for children living with other conditions. As
such, in the absence of primary data, proxies may be
used. Although few studies provided comparative infor-
mation on utility values between children and adults, a
few trends emerged. The study conducted by Mittmann
et al. suggested that utility values between adolescents
(e.g. 12-20 years of age) and young adults (e.g. 20-29
years of age) suffering from acne or asthma was similar
[10]. While limited by small sample sizes, other studies
i nt h ea r e ao fa c n ea l s os u g g e s t e ds i m i l a ru t i l i t yv a l u e s
between children and adults. Results of the only RCT
reporting utility values over time in children and adults
indicated similar utility gains between children and
adults with asthma who received usual care while a
higher utility gain was observed among children in the
intervention group [15].
The results also suggested that different methods may
lead to different utility values. While some studies, such
as Sung et al. [60], demonstrated somewhat similar utili-
ties derived from the HUI-2, HUI-3, and TTO methods
in children and adult patients with chronic disease
(range 0.92-0.95), the study by Moy et al. [29] showed
differences in utility when using HUI-3, SG or TTO
techniques (0.57, 0.91, 0.81, respectively) in a cohort of
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Page 7 of 11patients with asthma. It has been shown that different
methods used to collect utility data may yield different
HRQoL values in the same group of patients [89]. The
results of the three studies that used SG and TTO
methods in the same group of patients [18,29,54] sup-
ported our assumption that the SG method tends to
yield higher utility values than the time trade-off
method [89].
Different types of assessors (e.g. parents versus chil-
dren [60] or parents versus paediatricians [59]) used in
the estimation of utilities also led to differences in utili-
ties. Studies comparing utilities between patients and
proxies were common in the area of cancer. Those stu-
dies typically used parents, physicians and nurses as a
proxy. It has been argued that the use of medical staff
and teachers as proxies may give biased estimates when
determining utility values, since their rating of some
dimensions of HRQoL differ from the one of children
assessing their own health [90]. The rating of parents
for example may be affected by their knowledge about
health and health care and by their own current health
status [91].
Limitations associated with this review can be linked
to the broad research question (i.e. utilities in children
and adults), and the challenges associated with develop-
ing a literature search strategy that included all relevant
studies. Thus, there is a risk that some studies may have
been missed in the initial screening process as only one
reviewer screened the data. To minimize this risk, all
the references listed in the included studies, reviews,
commentaries or letters were manually searched to
identify potential studies. The grey literature was not
searched and unpublished utility evaluations may be
available through online services but were not included
in our review. Another limitation of our review is that
we did not assess the quality of the different studies, but
instead reviewed the main results and conclusions as
stated by the authors to determine some common
trends or directions among the various studies. It was
beyond the scope of this review to critically appraise the
methodological quality of studies. In the comparison of
utility values between children and adults, some differ-
ences in results may be due to chance or due to the
methods not being used correctly or consistently. The
r e l a t i v e l ys m a l ls a m p l es i z eo fs o m eo ft h es t u d i e sm a y
compromise the validity of the results. Small sample
sizes in HRQoL studies have also been reported else-
where [92]. Comparisons of utilities between children
and adults were especially difficult to assess in those
studies evaluating patients with cancer and diabetes due
to important differences in patient characteristics (e.g.
cancer types), study design (e.g. evaluation period) or
interventions. The majority of these studies were cross-
sectional, limiting our understanding of gain in utility
values over time which is almost always required for
economic evaluations. We restricted our search to speci-
fic utility instruments and conditions. For example, we
d i dn o ti n c l u d et h en e w l yd e v e l o p e dA Q o Lo rS F - 6 D .
Finally, our review was limited to asthma, skin diseases,
type I diabetes, certain types of cancer common to both
children and adults, and overall chronic conditions,
which may not represent the whole body of literature
that reports utility data in children or adolescents.
Expanding the search to other conditions or diseases
common to both children and adults that have a nega-
tive impact on HRQoL (e.g. epilepsy) is left for future
research. However, it is unlikely that the trends
observed in our studies would change by the expansion
of this review to other conditions common to children
and adults.
Despite these limitations, this review identified 77 stu-
dies reporting utility values derived from direct (SG or
TTO techniques) or indirect (pre-existing questionnaires
such as the EQ-5D and HUI) measurements across con-
ditions common to children and adults, that could be
used for future reference or for the conduct of sensitiv-
ity analyses in economic evaluations. The findings of
this review showed that the previous research on utili-
ties of children has primarily focused in the collection
of utilities in cancer patients (12 out of 18 studies)
which may be related to the development and validation
of the HUI-2. This review also indicated that few studies
have been conducted to estimate the utilities related to
children with asthma, diabetes or skin diseases.
Although there are no studies to compare our findings
with, our review complements the recent review of gen-
eric and disease specific instruments in children and
adolescents [5] by identifying studies reporting utilities
in children and adults with asthma, cancer, chronic dis-
ease, type 1 diabetes and skin diseases.
Conclusions
When interventions have an impact on HRQoL, utility
data are increasingly being used in economic evaluations
of health care technologies as they are required to calcu-
late QALYs in these studies. As such, reliable utility data
is therefore needed. As shown in this review of 77 stu-
dies, few studies have been set up to collect utilities in
children and adolescents, with the exception of studies
evaluating utilities in cancer patients. Canadian health
surveys have shown that utilities between adolescents
and young adults were similar in magnitude, suggesting
that in lack of better data, utility data obtained from
young adult populations may be used as a proxy for uti-
lities in children. Nevertheless, other studies have shown
that utility values differed when using different estima-
tion methods.
Tarride et al. Health and Quality of Life Outcomes 2010, 8:12
http://www.hqlo.com/content/8/1/12
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icine should be encouraged to conduct utility measure-
ments in their patients. This would increase the
availability of utility data in paediatric patients and pos-
sibly provide a greater understanding of the methodolo-
gical issues that are still present. For the time being,
analysts who conduct economic evaluations of interven-
tions among children or adolescents should conduct
comprehensive sensitivity analyses regarding the impact
of the utility values on their cost-effectiveness estimates.
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